The infection of Hepatitis B virus (HBV) can result in severe consequences, including chronic hepatitis, liver fibrosis, cirrhosis, and even liver cancer. Effective antiviral treatment has the potential to slow down the progression of the disease. HBV serum biomarkers play a crucial role in the dynamic management of chronic hepatitis B (CHB) patients. However, the conventional hepatitis B virus markers, such as hepatitis B serologic testing and HBV DNA, are insufficient to meet the clinical requirements. This review provided a comprehensive overview of the current research on the quantification of HBsAg and anti-HBc, HBV RNA and HBV core-associated antigen, which summarized the crucial role these markers play in the administration of antiviral medications, predicting the efficacy of treatment and anticipating the likelihood of virologic rebound following drug cessation, as well as assessing disease progression in CHB patients.
乙型肝炎病毒(HBV)感染可导致慢性肝炎、肝纤维化甚至肝硬化或肝癌等严重后果,有效的抗病毒治疗可以减缓疾病进展。乙肝病毒生物标志物在慢性乙型肝炎(CHB)患者全程动态化管理中具有重要作用,而经典乙肝病毒标志物(如乙肝两对半、HBV DNA)尚不能完全满足临床需求。本文综述了HBsAg定量、抗-HBc定量、HBV RNA和HBV核心相关抗原等HBV标志物的最新研究,总结了这些标志物在CHB患者抗病毒治疗中的使用、疗效预测和停药后复发风险预测,以及疾病进展风险评估等方面的作用。.
Keywords: Biomarkers; HBV RNA; HBcrAg; Hepatitis B virus.